Regencell Bioscience Holdings Limited (RGC)
USD 28.25
(-2.35%)
USD 28.25
(-2.35%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 | -152.77 Thousand USD | 100.0% |
| 2023 | -56.54 Thousand USD | -104.9% |
| 2022 | -27.59 Thousand USD | -271.14% |
| 2021 | -7436.00 USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | -100.0% |
| 2018 | 22.9 Million USD | 9.57% |
| 2017 | 20.9 Million USD | -6.7% |
| 2016 | 22.4 Million USD | 25.84% |
| 2015 | 17.8 Million USD | 0.0% |
| 2013 | 19 Million USD | 6.74% |
| 2012 | 17.8 Million USD | 21.09% |
| 2011 | 14.7 Million USD | 19.51% |
| 2010 | 12.3 Million USD | 53.75% |
| 2009 | 8 Million USD | 0.0% |
| 2007 | 8 Million USD | 0.0% |
| 2006 | 8 Million USD | 14.29% |
| 2005 | 7 Million USD | 16.67% |
| 2004 | 6 Million USD | 0.0% |
| 2002 | 6 Million USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - USD | 100.0% |
| 2024 Q2 | - USD | 0.0% |
| 2024 Q4 | -152.77 Thousand USD | 0.0% |
| 2023 Q1 | - USD | 100.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q4 | -56.54 Thousand USD | 0.0% |
| 2023 FY | -56.54 Thousand USD | -104.9% |
| 2023 Q3 | - USD | 0.0% |
| 2022 Q4 | -27.59 Thousand USD | 0.0% |
| 2022 FY | -27.59 Thousand USD | -271.14% |
| 2022 Q3 | - USD | 0.0% |
| 2022 Q1 | - USD | 100.0% |
| 2022 Q2 | - USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2021 FY | -7436.00 USD | 0.0% |
| 2021 Q4 | -7436.00 USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2019 FY | - USD | -100.0% |
| 2018 Q1 | 23.9 Million USD | -2.05% |
| 2018 Q2 | 22.9 Million USD | -4.18% |
| 2018 FY | 22.9 Million USD | 9.57% |
| 2017 Q4 | 24.4 Million USD | 4.72% |
| 2017 Q1 | 20.5 Million USD | -9.29% |
| 2017 Q2 | 20.9 Million USD | 1.95% |
| 2017 Q3 | 23.3 Million USD | 11.48% |
| 2017 FY | 20.9 Million USD | -6.7% |
| 2016 Q1 | 19.5 Million USD | 1.04% |
| 2016 FY | 22.4 Million USD | 25.84% |
| 2016 Q4 | 22.6 Million USD | -0.88% |
| 2016 Q3 | 22.8 Million USD | 1.79% |
| 2016 Q2 | 22.4 Million USD | 14.87% |
| 2015 FY | 17.8 Million USD | 0.0% |
| 2015 Q1 | 16.6 Million USD | -8.29% |
| 2015 Q4 | 19.3 Million USD | 4.89% |
| 2015 Q3 | 18.4 Million USD | 3.37% |
| 2015 Q2 | 17.8 Million USD | 7.23% |
| 2014 Q2 | 19 Million USD | 7.95% |
| 2014 Q4 | 18.1 Million USD | 2.26% |
| 2014 Q3 | 17.7 Million USD | -6.84% |
| 2014 Q1 | 17.6 Million USD | -3.83% |
| 2013 FY | 19 Million USD | 6.74% |
| 2013 Q4 | 18.3 Million USD | 12.96% |
| 2013 Q2 | 17.8 Million USD | 14.1% |
| 2013 Q3 | 16.2 Million USD | -8.99% |
| 2013 Q1 | 15.6 Million USD | -5.45% |
| 2012 Q2 | 14.8 Million USD | 10.45% |
| 2012 FY | 17.8 Million USD | 21.09% |
| 2012 Q4 | 16.5 Million USD | 3.77% |
| 2012 Q3 | 15.9 Million USD | 7.43% |
| 2012 Q1 | 13.4 Million USD | -11.26% |
| 2011 Q2 | 14.7 Million USD | 18.55% |
| 2011 Q1 | 12.4 Million USD | -15.07% |
| 2011 Q3 | 13.3 Million USD | -9.52% |
| 2011 FY | 14.7 Million USD | 19.51% |
| 2011 Q4 | 15.1 Million USD | 13.53% |
| 2010 Q1 | 10 Million USD | -16.67% |
| 2010 Q3 | 13 Million USD | 5.69% |
| 2010 Q4 | 14.6 Million USD | 12.31% |
| 2010 Q2 | 12.3 Million USD | 23.0% |
| 2010 FY | 12.3 Million USD | 53.75% |
| 2009 FY | 8 Million USD | 0.0% |
| 2009 Q1 | 7 Million USD | -30.0% |
| 2009 Q2 | 8 Million USD | 14.29% |
| 2009 Q3 | 9 Million USD | 12.5% |
| 2009 Q4 | 12 Million USD | 33.33% |
| 2008 Q4 | 10 Million USD | 42.86% |
| 2008 Q2 | 8 Million USD | 0.0% |
| 2008 Q3 | 7 Million USD | -12.5% |
| 2008 Q1 | 8 Million USD | -11.11% |
| 2007 Q4 | 9 Million USD | 12.5% |
| 2007 FY | 8 Million USD | 0.0% |
| 2007 Q3 | 8 Million USD | 0.0% |
| 2007 Q2 | 8 Million USD | 14.29% |
| 2007 Q1 | 7 Million USD | -12.5% |
| 2006 Q4 | 8 Million USD | 14.29% |
| 2006 Q3 | 7 Million USD | 0.0% |
| 2006 Q2 | 7 Million USD | 0.0% |
| 2006 Q1 | 7 Million USD | -17.65% |
| 2006 FY | 8 Million USD | 14.29% |
| 2005 Q2 | 7 Million USD | -2.78% |
| 2005 FY | 7 Million USD | 16.67% |
| 2005 Q1 | 7.2 Million USD | -10.0% |
| 2005 Q3 | 7.1 Million USD | 1.43% |
| 2005 Q4 | 8.5 Million USD | 19.72% |
| 2004 FY | 6 Million USD | 0.0% |
| 2004 Q2 | 6 Million USD | 0.0% |
| 2004 Q1 | 6 Million USD | -25.0% |
| 2004 Q4 | 8 Million USD | 33.33% |
| 2004 Q3 | 6 Million USD | 0.0% |
| 2003 Q4 | 8 Million USD | 33.33% |
| 2003 Q1 | 6 Million USD | -14.29% |
| 2003 Q2 | 6 Million USD | 0.0% |
| 2003 Q3 | 6 Million USD | 0.0% |
| 2002 Q3 | 7.02 Million USD | 0.0% |
| 2002 FY | 6 Million USD | 0.0% |
| 2002 Q4 | 7 Million USD | -0.4% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Journey Medical Corporation | 10.2 Million USD | 101.497% |
| ANI Pharmaceuticals, Inc. | 111.19 Million USD | 100.137% |
| Aquestive Therapeutics, Inc. | 6.76 Million USD | 102.257% |
| Pacira BioSciences, Inc. | 104.35 Million USD | 100.146% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | 102.664% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | 102.664% |
| SCYNEXIS, Inc. | - USD | Infinity% |
| Safety Shot Inc | 1.86 Million USD | 108.171% |
| Alpha Teknova, Inc. | 11.59 Million USD | 101.318% |
| Collegium Pharmaceutical, Inc. | 32.33 Million USD | 100.473% |
| Bright Green Corporation | - USD | Infinity% |
| Dynavax Technologies Corporation | 53.29 Million USD | 100.287% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 100.233% |
| Cosmos Health Inc. | 4.78 Million USD | 103.19% |
| PainReform Ltd. | - USD | Infinity% |
| China SXT Pharmaceuticals, Inc. | 809.75 Thousand USD | 118.867% |
| Embecta Corp. | 152.1 Million USD | 100.1% |
| Intra-Cellular Therapies, Inc. | 11.64 Million USD | 101.312% |
| Procaps Group, S.A. | 96.83 Million USD | 100.158% |
| Theratechnologies Inc. | 6.06 Million USD | 102.519% |
| Harrow Health, Inc. | 10.86 Million USD | 101.406% |
| Sonoma Pharmaceuticals, Inc. | 2.71 Million USD | 105.619% |
| Biofrontera Inc. | 10.9 Million USD | 101.401% |
| DURECT Corporation | 2.21 Million USD | 106.885% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 100.197% |
| Cronos Group Inc. | 30.33 Million USD | 100.504% |
| OptiNose, Inc. | 8.05 Million USD | 101.897% |
| Ironwood Pharmaceuticals, Inc. | 1.00 USD | 15277900.0% |
| Kala Pharmaceuticals, Inc. | - USD | Infinity% |
| RedHill Biopharma Ltd. | 5.69 Million USD | 102.681% |
| Organogenesis Holdings Inc. | 28.25 Million USD | 100.541% |
| Guardion Health Sciences, Inc. | 2.67 Million USD | 105.707% |
| Cumberland Pharmaceuticals Inc. | 4.6 Million USD | 103.315% |
| Radius Health, Inc. | 278.64 Million USD | 100.055% |
| Universe Pharmaceuticals INC | 3.34 Million USD | 104.57% |
| ProPhase Labs, Inc. | 3.84 Million USD | 103.978% |
| Phibro Animal Health Corporation | 265.91 Million USD | 100.057% |
| Procaps Group S.A. | 96.83 Million USD | 100.158% |
| Alvotech | 74.43 Million USD | 100.205% |
| TherapeuticsMD, Inc. | - USD | Infinity% |
| Viatris Inc. | 3.46 Billion USD | 100.004% |
| Rockwell Medical, Inc. | 5.87 Million USD | 102.602% |
| Aytu BioPharma, Inc. | 12.63 Million USD | 101.209% |
| SIGA Technologies, Inc. | 64.21 Million USD | 100.238% |
| Tilray Brands, Inc. | 252.08 Million USD | 100.061% |
| Lifecore Biomedical, Inc. | 39.97 Million USD | 100.382% |
| Shineco, Inc. | 1.58 Million USD | 109.618% |
| PetIQ, Inc. | 159.3 Million USD | 100.096% |
| Incannex Healthcare Limited | -10.01 Million USD | 98.475% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | 100.399% |
| Alimera Sciences, Inc. | 1.87 Million USD | 108.131% |
| Silver Spike Investment Corp. | - USD | Infinity% |
| Assertio Holdings, Inc. | 37.68 Million USD | 100.405% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | Infinity% |
| Petros Pharmaceuticals, Inc. | 1.61 Million USD | 109.487% |
| Clever Leaves Holdings Inc. | 4.48 Million USD | 103.408% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | 160.066% |
| Avadel Pharmaceuticals plc | 10.38 Million USD | 101.472% |
| Hempacco Co., Inc. | 2.54 Million USD | 106.009% |
| Talphera, Inc. | - USD | Infinity% |
| Alvotech | 74.43 Million USD | 100.205% |
| Eagle Pharmaceuticals, Inc. | 47.79 Million USD | 100.32% |
| Lantheus Holdings, Inc. | 64.02 Million USD | 100.239% |
| Currenc Group, Inc. | 732.91 Thousand USD | 120.845% |
| Kamada Ltd. | 87.74 Million USD | 100.174% |
| Indivior PLC | 141.79 Million USD | 100.108% |
| Evoke Pharma, Inc. | 481.84 Thousand USD | 131.707% |
| Flora Growth Corp. | 8.5 Million USD | 101.796% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | 160.066% |
| Evolus, Inc. | 10.99 Million USD | 101.389% |
| HUTCHMED (China) Limited | 50.25 Million USD | 100.304% |
| Amphastar Pharmaceuticals, Inc. | 105.83 Million USD | 100.144% |
| Akanda Corp. | 1.28 Million USD | 111.872% |